Kids with ADHD often complain that they are bored. But what does that really mean? And many are also depressed. Does treating the ADHD help these symptoms? We looked a study that tries to break this down and give us a way forward, while offering some new insights on the relationships between ADHD, mood and boredom - important and useful symptoms to track.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

Does ADHD bring creative strengths? Can stimulants dampen creative thought? New research suggests they can, but the effect varies by patient.

Many of us have had very little training about the specifics of reading disorders ie dyslexia. Learn what it is and what to do about this problem, which typically lies underneath the surface of the secondary psychiatric impact that obscures our ability to recognize and address it. Bet you didn’t know that there are actually medication studies on treating dyslexia too.

Russell Barkley, PhD, discusses the enormity of the health consequences and early mortality associated with ADHD. The range and likely mechanism of long-term effects of ADHD are discussed, and we examine the role of assertive treatment in childhood and adolescence.

We examine current methylphenidate dosing and unpack what the research tells us about prescribing beyond conventional limits when clinically indicated for children and adolescents.

There are so many alleged herbal remedies touted to treat psychiatric disorders. See our take on this head to head study of Crocus Sativus aka. Saffron versus methylphenidate in ADHD.

From the Oval Office to the college dorm, stimulants are often used as performance-enhancing drugs. The ethics of this practice are questionable, but so is the science. New research suggests their pro-cognitive effects are mild at best and come with an unexpected cost on working memory.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.